Mountain Crest Acquisition II (Mountain Crest Acquisition II) Capex-to-Revenue : 0.00 (As of Oct. 2020)

View and export this data going back to 2021. Start your Free Trial

What is Mountain Crest Acquisition II Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Mountain Crest Acquisition II's Capital Expenditure for the six months ended in Oct. 2020 was $0.00 Mil. Its Revenue for the six months ended in Oct. 2020 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Mountain Crest Acquisition II Capex-to-Revenue Historical Data

The historical data trend for Mountain Crest Acquisition II's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mountain Crest Acquisition II Capex-to-Revenue Chart

Mountain Crest Acquisition II Annual Data

Trend

Dec20

Capex-to-Revenue

Mountain Crest Acquisition II Semi-Annual Data
	Oct20
Capex-to-Revenue	-

Competitive Comparison of Mountain Crest Acquisition II's Capex-to-Revenue

For the Shell Companies subindustry, Mountain Crest Acquisition II's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mountain Crest Acquisition II's Capex-to-Revenue Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Mountain Crest Acquisition II's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Mountain Crest Acquisition II's Capex-to-Revenue falls into.

Mountain Crest Acquisition II Capex-to-Revenue Calculation

Mountain Crest Acquisition II's Capex-to-Revenue for the fiscal year that ended in Dec. 2020 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Mountain Crest Acquisition II's Capex-to-Revenue for the quarter that ended in Oct. 2020 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Mountain Crest Acquisition II (NAS:MCADU) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Mountain Crest Acquisition II Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mountain Crest Acquisition II's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Mountain Crest Acquisition II (Mountain Crest Acquisition II) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Mountain Crest Acquisition Corp II (NAS:MCADU) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

311 West 43rd Street, 12th Floor, New York, NY, USA, 10036

Website

Mountain Crest Acquisition Corp II is a blank check company.

Executives

Frank Karbe	director, officer: See Remarks	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Elder Granger	director	5176 S. LEWISTON WAY, CENTENNIAL CO 80015
Richard H Carmona	director	1221 BROADWAY, OAKLAND CA 94612
Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Risa J Lavizzo-mourey	director	GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Andrew J. Armanino	director	C/O CALIFORNIA BANCORP, 1300 CLAY STREET, FIFTH FLOOR, OAKLAND CA 94612
David P Perry	director, 10 percent owner, officer: See Remarks	1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Suying Liu	director	311 WEST 43RD STREET, 12TH FLOOR, NEW YORK NY 10036
Kevin Appelbaum, Or His Successor(s), As Trustee Of The Kevin Appelbaum Revocable Trust Under Revocable Trust Declaration Dated 5/16/2020, As Amended	10 percent owner	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
David P. Perry 2015 Trust	10 percent owner	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Mark A. Berman	officer: Chief Medical Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Kevin J Appelbaum	director, 10 percent owner, officer: Chief Executive Officer	4160 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Mark Heinen	officer: See Remarks	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Justin Zamirowski	officer: Chief Commercial Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Kristin Wynholds	officer: Chief Product Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104